BRPI0512854A - terapia adjuvante aperfeiçoada para tumores que expressam g250 - Google Patents
terapia adjuvante aperfeiçoada para tumores que expressam g250Info
- Publication number
- BRPI0512854A BRPI0512854A BRPI0512854-4A BRPI0512854A BRPI0512854A BR PI0512854 A BRPI0512854 A BR PI0512854A BR PI0512854 A BRPI0512854 A BR PI0512854A BR PI0512854 A BRPI0512854 A BR PI0512854A
- Authority
- BR
- Brazil
- Prior art keywords
- adjuvant therapy
- expressing tumors
- improved adjuvant
- antigen
- improved
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000009098 adjuvant therapy Methods 0.000 title 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 abstract 3
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000683 nonmetastatic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58467904P | 2004-07-02 | 2004-07-02 | |
| PCT/EP2005/006994 WO2006002889A2 (en) | 2004-07-02 | 2005-06-29 | Improved adjuvant therapy of g250-expressing tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0512854A true BRPI0512854A (pt) | 2008-04-08 |
Family
ID=35431139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0512854-4A BRPI0512854A (pt) | 2004-07-02 | 2005-06-29 | terapia adjuvante aperfeiçoada para tumores que expressam g250 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7691375B2 (enExample) |
| EP (2) | EP1763367A2 (enExample) |
| JP (1) | JP2008505143A (enExample) |
| KR (1) | KR101205289B1 (enExample) |
| CN (1) | CN101052416B (enExample) |
| AU (1) | AU2005259481B2 (enExample) |
| BR (1) | BRPI0512854A (enExample) |
| CA (1) | CA2566950A1 (enExample) |
| DK (1) | DK2497497T3 (enExample) |
| ES (1) | ES2641089T3 (enExample) |
| MX (1) | MXPA06013240A (enExample) |
| RU (2) | RU2371198C2 (enExample) |
| WO (1) | WO2006002889A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077081A1 (en) * | 2001-02-07 | 2004-04-22 | Egbert Oosterwijk | Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| US20090162382A1 (en) * | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
| AU2003280442B2 (en) * | 2002-07-01 | 2009-02-05 | Wilex Ag | Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas |
| WO2011034182A1 (ja) | 2009-09-18 | 2011-03-24 | 三菱化学株式会社 | 肝細胞癌マーカー |
| RU2442983C1 (ru) * | 2011-01-14 | 2012-02-20 | Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы | Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции |
| AU2013328580B2 (en) | 2012-10-12 | 2016-01-21 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| NZ712023A (en) * | 2013-02-22 | 2019-10-25 | Wilex Ag | Caix stratification based cancer treatment |
| CN105209077B (zh) | 2013-03-13 | 2019-06-11 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓以及其结合物 |
| EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US20200023072A1 (en) | 2016-10-11 | 2020-01-23 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| AU2021362997A1 (en) | 2021-11-03 | 2024-05-16 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0366707A1 (en) * | 1987-05-06 | 1990-05-09 | OOSTERWIJK, Egbert | Monoclonal antibodies to renal cell carcinoma |
| US5387676A (en) * | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
| US6417337B1 (en) * | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| ES2531909T3 (es) * | 2001-02-07 | 2015-03-20 | Wilex Ag | Método de producción de anticuerpos recombinantes contra tumores |
| WO2003068920A2 (en) | 2002-02-13 | 2003-08-21 | Ludwig Institute For Cancer Research | Humanized gm-csf antibodies |
| AU2003280442B2 (en) * | 2002-07-01 | 2009-02-05 | Wilex Ag | Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas |
| RU2257200C1 (ru) * | 2004-05-12 | 2005-07-27 | Кутушов Михаил Владимирович | Лекарственное средство |
-
2005
- 2005-06-29 AU AU2005259481A patent/AU2005259481B2/en not_active Expired
- 2005-06-29 JP JP2007519679A patent/JP2008505143A/ja active Pending
- 2005-06-29 WO PCT/EP2005/006994 patent/WO2006002889A2/en not_active Ceased
- 2005-06-29 MX MXPA06013240A patent/MXPA06013240A/es active IP Right Grant
- 2005-06-29 US US11/630,170 patent/US7691375B2/en active Active
- 2005-06-29 ES ES12171081.8T patent/ES2641089T3/es not_active Expired - Lifetime
- 2005-06-29 RU RU2007104040/14A patent/RU2371198C2/ru not_active IP Right Cessation
- 2005-06-29 BR BRPI0512854-4A patent/BRPI0512854A/pt not_active Application Discontinuation
- 2005-06-29 CA CA002566950A patent/CA2566950A1/en not_active Abandoned
- 2005-06-29 CN CN2005800205034A patent/CN101052416B/zh not_active Expired - Fee Related
- 2005-06-29 EP EP05775970A patent/EP1763367A2/en not_active Ceased
- 2005-06-29 EP EP12171081.8A patent/EP2497497B1/en not_active Expired - Lifetime
- 2005-06-29 KR KR1020067027704A patent/KR101205289B1/ko not_active Expired - Fee Related
- 2005-06-29 DK DK12171081.8T patent/DK2497497T3/en active
-
2009
- 2009-06-10 RU RU2009122344/15A patent/RU2519340C2/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009122344A (ru) | 2010-12-20 |
| AU2005259481B2 (en) | 2010-04-22 |
| US20070207157A1 (en) | 2007-09-06 |
| CA2566950A1 (en) | 2006-01-12 |
| US7691375B2 (en) | 2010-04-06 |
| DK2497497T3 (en) | 2017-08-14 |
| CN101052416B (zh) | 2013-07-10 |
| RU2519340C2 (ru) | 2014-06-10 |
| RU2371198C2 (ru) | 2009-10-27 |
| EP2497497B1 (en) | 2017-06-21 |
| WO2006002889A2 (en) | 2006-01-12 |
| KR20070036085A (ko) | 2007-04-02 |
| KR101205289B1 (ko) | 2012-11-27 |
| EP1763367A2 (en) | 2007-03-21 |
| ES2641089T3 (es) | 2017-11-07 |
| MXPA06013240A (es) | 2007-02-28 |
| EP2497497A1 (en) | 2012-09-12 |
| RU2007104040A (ru) | 2008-08-10 |
| AU2005259481A1 (en) | 2006-01-12 |
| CN101052416A (zh) | 2007-10-10 |
| WO2006002889A3 (en) | 2006-10-05 |
| JP2008505143A (ja) | 2008-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0512854A (pt) | terapia adjuvante aperfeiçoada para tumores que expressam g250 | |
| NO20084479L (no) | Antitumor celleantigen antistoff terapi | |
| BRPI0916138A2 (pt) | "método de tratamento de um sujeito diagnosticado com câncer de mama localmente, kit para tratar câncer de mama metastático em um sujeito humano, uso de um anticorpo antivegf na fabricação de um medicamento para tratar câncer de mama localmente recidivado ou metastático em um sujeito e anticorpo anti-vegf para uso em um método de tratamento de câncer de mama localmente recidivado ou metastático em um sujeito" | |
| CY2017013I2 (el) | ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ | |
| MX2008012754A (es) | Composiciones de anticuerpos y metodos para tratamiento de enfermedad neoplastica. | |
| NO20084546L (no) | Diagnostikk og behandlinger for tumorer | |
| ECSP088733A (es) | Anticuerpos anti-5t4 y usos de los mismos | |
| NO20064193L (no) | fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser | |
| CR9477A (es) | Numero de copias del gen del receptor del factor de crecimiento epidermico | |
| CR9512A (es) | Metodos para el tratamiento de tumores de cerebro con anticuerpos | |
| WO2005103081A3 (en) | Human monoclonal antibodies against cd20 | |
| ATE520007T1 (de) | Bildgebungsgeometrie | |
| DK2109623T3 (da) | Cancerbehandling med anti-IL-1-antistoffer | |
| NO20092052L (no) | Antistoffer og immunkonjugater, og anvendelser derav | |
| CY1109468T1 (el) | Χρησεις ανταγωνιστων της il-23. σχετικα αντιδραστηρια | |
| EA021242B9 (ru) | Антитела к остеопротегерин лиганду (опгл) | |
| JO3625B1 (ar) | بروتينات رابطة للأنتيجين cd27l | |
| MX2009006779A (es) | Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana. | |
| MX374906B (es) | Nuevos inmunoconjugados | |
| NO20082381L (no) | Bispesifikke ligander med bindingsspesifisitet til celleoverflate mal og fremgangsmater for anvendelse derav | |
| MX2009009787A (es) | Mutaciones de k-ras y terapia con anticuerpos anti-egfr. | |
| CY1108645T1 (el) | Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη | |
| WO2009046294A3 (en) | Treatment of proliferative disorders using antibodies to psma | |
| CR10143A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer | |
| DE602005023488D1 (de) | Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: WILEX AG (DE) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080117818/RJ DE 08/09/2008. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |